Partnership helps expand population access to cutting-edge genomic tests

SAO PAULO, Dec. 19, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has recently partnered with Sabin Group, one of the largest diagnostic laboratories in Brazil, to improve health detection through genetic sequencing technology. The collaboration aims to expand the porfolio of exams and enlarge the access of Brazilians to innovative genomics tests offered by Sabin.

Sabin Group has been operating in fifteen states of Brazil for 40 years. With thousands of employees, Sabin is now serving more than 7 million customers annually, offering a wide range of clinical analysis, diagnostic imaging, vaccination and examination services.

The partnership between MGI and Sabin is a fundamental step towards the development of personalized medicine in Brazil. By expanding access to advanced genetic sequencing technologies, it is possible to provide more accurate diagnoses and personalize treatments according to each patient's genetic profile. In addition to improving clinical outcomes, it also promotes a more preventive and efficient approach to healthcare, which can transform medical practice in the country.

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

"The combination of our cutting-edge technology with Sabin's vast network and expertise will create a unique synergy that can transform the Brazilian healthcare system. Sabin has a strong and consolidated presence in the country and, by incorporating our genetic sequencing solutions, we can offer more accurate and accessible diagnostics to a broad patient base. This partnership has the potential to raise the standard of care and promote more personalized and efficient medicine in the country," Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil, explains.

"The implementation of MGI's sequencing technology at Sabin has significantly advanced our genomic operations. With expanded sequencing capacity and the ability to generate large volumes of high-quality data, we can now perform more comprehensive and precise analyses, enhancing diagnostics and driving the evolution of personalized medicine. This partnership has also seamlessly integrated into our laboratory environment, providing innovative solutions that boost efficiency and support mutual growth. The outcomes are both reliable and high-quality, underscoring our commitment to delivering the best care to our patients while leveraging cutting-edge advancements in genomics", says Rafael J